Association of Dyslipidemia with Renal Cell Carcinoma: A 1:2 Matched Case-Control Study

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhang, Chunfang ^a   Yu, Luping ^a   Xu, Tao ^a   Hao, Yichang ^a   Zhang, Xiaowei ^a   Liu, Zhenhua ^a   Xiao, Yunbei ^a   Wang, Xiaofeng ^a   Zeng, Qiang ^b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY CARCINOMA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIPIDS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; RISK FACTORS; YOUNG ADULT;

EID: 84875471851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059796     Document Type: Article

References (36)

1. Pantuck AJ, Zisman A, Belldegrun AS, (2001) The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623.
2. La Vecchia C, Levi F, Lucchini F, E N, (1992) Descriptive epidemiology of kidney cancer in Europe. J Nephrol 5: 7.
3. Liu S, Semenciw R, Morrison H, Schanzer D, Mao Y, (1997) Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health 88: 99-104.
4. Wunderlich H, Schumann S, Jantitzky V, Moravek P, Podhola M, et al. (1998) Increase of renal cell carcinoma incidence in central Europe. Eur Urol 33: 538-541.
5. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr, (1999) Rising incidence of renal cell cancer in the United States. JAMA 281: 1628-1631.
6. McCredie M, Stewart J, Smith D, Supramaniam R, Williams S, (1999) Observations on the effect of abolishing analgesic abuse and reducing smoking on cancers of the kidney and bladder in New South Wales, Australia, 1972-1995. Cancer Cause Control 10: 303-311.
7. Jin F, Devesa SS, Chow WH, Zheng W, Ji BT, et al. (1999) Cancer incidence trends in urban shanghai, 1972-1994: an update. Int J Cancer 83: 435-440.
8. Rini BI, Campbell SC, Escudier B, (2009) Renal cell carcinoma. The Lancet 373: 1119-1132.
9. Choi MY, Jee SH, Sull JW, Nam CM, (2005) The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int 67: 647-652.
10. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE, (2007) Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 166: 932-940.
11. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, et al. (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166: 1871-1877.
12. Nicodemus KK, Sweeney C, Folsom AR, (2004) Evaluation of dietary, medical and lifestyle risk factors for incident kidney cancer in postmenopausal women. Int J Cancer 108: 115-121.
13. Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, et al. (2009) Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 101: 1202-1206.
14. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH, (2007) Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol 50: 409-418.
15. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH, (2008) Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 52: 1141-1147.
16. Warnick GR, Knopp RH, Fitzpatrick V, Branson L, (1990) Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 36: 15-19.
17. Bowers K, Albanes D, Limburg P, Pietinen P, Taylor PR, et al. (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164: 652-664.
18. Asano K, Kubo M, Yonemoto K, Doi Y, Ninomiya T, et al. (2008) Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer 122: 909-914.
19. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F, (2000) Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 71: 569-574.
20. Panagiotakos DB, Pitsavos C, Polychronopoulos E, Chrysohoou C, Menotti A, et al. (2005) Total cholesterol and body mass index in relation to 40-year cancer mortality (the Corfu cohort of the seven countries study). Cancer Epidemiol Biomarkers Prev 14: 1797-1801.
21. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D, (2002) A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 13: 417-426.
22. Brock KE, Gridley G, Chiu BC, Ershow AG, Lynch CF, et al. (2009) Dietary fat and risk of renal cell carcinoma in the USA: a case-control study. Br J Nutr 101: 1228-1238.
23. Andreotti G, Chen J, Gao YT, Rashid A, Chang SC, et al. (2008) Serum lipid levels and the risk of biliary tract cancers and biliary stones: A population-based study in China. Int J Cancer 122: 2322-2329.
24. Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG, (2011) Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 103: 508-519.
25. Jafri H, Alsheikh-Ali AA, Karas RH, (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. J Am Coll Cardiol 55: 2846-2854.
26. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, et al. (2009) Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 18: 2814-2821.
27. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, et al. (2000) Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med 6: 307-311.
28. Fiorenza AM, Branchi A, Sommariva D, (2000) Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 30: 141-145.
29. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, Weinstein SJ, et al. (2007) Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma. Cancer Res 67: 5569-5574.
30. Tall AR (1998) An overview of reverse cholesterol transport. Eur Heart J 19 Suppl A: A31-35.
31. Nofer JR, Junker R, Pulawski E, Fobker M, Levkau B, et al. (2001) High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost 85: 730-735.
32. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, et al. (2001) Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem 276: 34480-34485.
33. von Eckardstein A, Hersberger M, Rohrer L, (2005) Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 8: 147-152.
34. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV, (1981) Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. Am J Med 71: 595-602.
35. Vitols S, Gahrton G, Bjorkholm M, Peterson C, (1985) Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 2: 1150-1154.
36. Linehan WM, Srinivasan R, Schmidt LS, (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7: 277-285.